Evidence map›Paper›PMID 27118234›Full record

ReviewCurrent heart failure reports2016

Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?

Ruth F Dubin, Sanjiv J Shah

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ruth F DubinDivision of Nephrology, Department of Medicine, San Francisco VA Medical Center/University of California, San Francisco, 4150 Clement St., Box 111A1, San Francisco, CA, 94121, USA. ruth.dubin@ucsf.edu.
Sanjiv J ShahDivision of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
Northwestern University · USSan Francisco VA Medical Center · US

Funding

Transition from Risk Factors to Early HF: Prevalence, Pathogenesis, and PhenomicsR01HL127028 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BERTONI, ALAIN GERALD, SHAH, SANJIV J · 2015 to 2018
$6.5M
Study of Cardiac Mechanics in Systemic HypertensionR01HL107577 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHAH, SANJIV J · 2011 to 2019
$4.1M
Elucidating Pathways of Vascular Dysfunction and Myocardial Injury in ESRDK23DK092354 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBIN, RUTH · 2012 to 2016
$878k
Novel Echocardiographic Methods to Characterize Heart Failure in ESRDR03DK104013 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBIN, RUTH · 2015 to 2016
$142k
NHLBI NIH HHS R01 HL107577NHLBI NIH HHS R01 HL127028NIDDK NIH HHS K23 DK092354NIDDK NIH HHS R03 DK104013
6 · The paper itself

Abstract

Heart failure in the setting of chronic kidney disease (CKD) is an increasingly common scenario and carries a poor prognosis. Clinicians lack tools for primary or secondary heart failure prevention in patients with cardiorenal syndromes. In patients without CKD, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) and statins mitigate cardiovascular risk in large part due to salutary effects on the endothelium. In the setting of CKD, use of these therapies is limited by adverse effects of hyperkalemia in pre-dialysis CKD (ACE-I/ARB), or potential increased risk of stroke in end-stage renal disease (statins). The soluble guanylate cyclase (sGC) stimulators are a novel class of medications that promote endothelial and myocardial function with no known risk of hyperkalemia or stroke. In this review, we discuss the evidence emerging from recent clinical trials of sGC stimulators in pulmonary hypertension and heart failure, the diseased pathways involved in cardiorenal syndromes likely to be restored by sGC stimulators, and several strategies for designing future clinical trials of cardiorenal syndromes that might shorten the timeline for discovery and approval of effective cardiovascular therapies in these high-risk patients.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCardio-Renal SyndromeCardiovascular DiseasesEnzyme ActivationHeart FailureHumansRisk FactorsSoluble Guanylyl CyclaseAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsSoluble Guanylyl CyclaseCyclic GMPHeart failureRenal diseaseSoluble guanylate cyclaseTherapy

Identifiers

PMID27118234
OpenAlexW2345266340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.